Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

Johannes F. E. Mann*, Marcel H. A. Muskiet

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)314-318
Number of pages5
JournalKidney International
Issue number2
Publication statusPublished - 1 Feb 2021

Cite this